 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || ALE.C04 / Alentis Therap
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Study of ALE.C04 in Patients With Head and Neck Cancer (clinicaltrials.gov) - Dec 31, 2023
P1/2, N=220, Recruiting, Sponsor: Alentis Therapeutics AG
- |||| ALE.C04 / Alentis Therap
Enrollment open, Combination therapy, Metastases: Study of ALE.C04 in Patients With Head and Neck Cancer (clinicaltrials.gov) - Nov 22, 2023
P1/2, N=220, Recruiting, Sponsor: Alentis Therapeutics AG
Not yet recruiting --> Recruiting
- ||||| ALE.C04 / Alentis Therap
New P1/2 trial, Combination therapy, Metastases: Study of ALE.C04 in Patients With Head and Neck Cancer (clinicaltrials.gov) - Sep 26, 2023
P1/2, N=220, Not yet recruiting, Sponsor: Alentis Therapeutics AG
- ALE.C04 / Alentis Therap
CLAUDIN-1 targeting antibody ALE.C04 drives single activity and restores anti-PD1 efficacy in solid tumors (Section 36; Poster Board #18) - Mar 14, 2023 - Abstract #AACR2023AACR_6767;
ALE.C04 perturbs the interface between CLDN1+ tumor cells and the stroma, thus restoring immune cell infiltration. Our pre-clinical data showed that: i) NJ-CLDN1 is a novel and druggable target in solid tumors ii) ALE.C04 is a selective anti-CLDN1 antibody capable of driving anti-tumor activity as both single agent and in combination with anti-PD1.
- ALE.C04 / Alentis Therap
CLAUDIN-1 Targeting Antibodies in Solid Tumors: from ALE.C04 to CLAUDIN-1 Oncology Platform (Foyer ABC) - Oct 21, 2022 - Abstract #ESMOIO2022ESMO_IO_346;
Importantly, ALE.C04 restored T cell infiltration and CPI efficacy in a mouse model for liver tumor . Based on our pre-clinical data, rationale and safety profile, we plan a phase 1b study with ALE.C04 in combination with CPIs in solid tumors.